Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Tower Urology

Neither a doctor nor a teaching hospital

Research payments

$1,530,429

165 payments

Through program year 2025, Tower Urology is reported as receiving $1,530,429 in research payments, across 165 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $261,425 27
2024 Research $324,842 42
2023 Research $25,717 7
2022 Research $14,928 9
2021 Research $293,860 24
2020 Research $249,416 35
2019 Research $360,241 21

Breakdown

Who paid Research payments · program years 2019–2025
  1. Progenics Pharmaceuticals, Inc. $619,661 49 payments
  2. Blue Earth Diagnostics Limited $515,981 38 payments
  3. Pfizer Inc. $125,238 8 payments
  4. Boston Scientific Corporation $76,000 11 payments
  5. AbbVie, Inc. $62,843 20 payments
  6. Sumitomo Pharma America, Inc. $39,250 6 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $28,231 16 payments
  8. AstraZeneca Pharmaceuticals LP $25,975 4 payments
  9. AstraZeneca UK Limited $19,700 1 payment
  10. Astellas Pharma Global Development $11,626 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. Study of 18F DCFPyL PET CT Imaging in Patients With Suspected Recurrence of Prostate Cancer CONDOR $259,186 8 payments
  2. Pylarify Pet-Ct Or Pet-Mri in Men With Favorable Intermediate Risk -Fir- Prostate Cancer -Mirror $223,299 16 payments
  3. A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Men With Suspected Prostate Cancer Recurrence Based on Elevated PSA Following Prior Therapy. $145,123 4 payments
  4. Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy $110,851 10 payments
  5. A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer $103,227 4 payments
  6. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies $96,988 3 payments
  7. Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE) $87,057 12 payments
  8. It Matters $76,000 11 payments
  9. Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT) $64,804 7 payments
  10. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $39,334 11 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $259,186 8 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record